Skip to main content
SpringerLink
Log in

Fighting Cancer Resistance: An Overview

  • Protocol
  • First Online:
Cancer Cell Signaling

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2174))

Abstract

The inherent or developed resistance of many cancer cells to chemotherapy and irradiation is actually the main challenge to overcome in cancer treatment. It is well known that cancer cells are characterized by several hallmarks, and it seems that the ability to evolve ways to evade stressful conditions and killing therapies must be consider another typical characteristic displayed by all malignant cells. This overview aims to provide a concise description of the main mechanisms involved in the promotion of resistance to anticancer therapy and to describe the most frequent challenges faced in the war against cancer therapy resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Assaraf YG, Brozovic A, Gonçalves AC et al (2019) The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resist Updat 46:100645

    Article  PubMed  Google Scholar 

  2. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B (2017) The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull 7:339–348

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT (2013) Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci 110:E170–E179

    Article  CAS  PubMed  Google Scholar 

  4. Delou JMA, Souza ASO, Souza LCM, Borges HL (2019) Highlights in resistance mechanism pathways for combination therapy. Cell 8:1013. https://doi.org/10.3390/cells8091013

    Article  CAS  Google Scholar 

  5. Marquez RT, Tsao BW, Faust NF, Xu L (2013) Drug resistance and molecular cancer therapy: apoptosis versus autophagy. In: Apoptosis (Chapter 8). InTech Open Science, London, pp 155–196

    Google Scholar 

  6. Schimmer AD (2004) Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 64(20):7183–7190

    Article  CAS  PubMed  Google Scholar 

  7. Mokhtari RB, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H (2015) Combination therapy in combating cancer. Oncotarget 8:38022–38043

    Article  Google Scholar 

  8. Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S (2019) Combining epigenetic drugs with other therapies for solid tumours-past lessons and future promise. Nat Rev Clin Oncol 17(2):91–107. https://doi.org/10.1038/s41571-019-0267-4

    Article  CAS  PubMed  Google Scholar 

  9. Boumahdi S, de Sauvage FJ (2019) The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discov doi 19(1):39–56. https://doi.org/10.1038/s41573-019-0044-1

    Article  CAS  Google Scholar 

  10. Tan CS, Kumarakulasinghe NB, Huang YQ, Ang YLE et al (2018) Third generation EGFR TKIs: current data and future directions. Mol Cancer 17(1):29

    Article  PubMed  PubMed Central  Google Scholar 

  11. Khaliq M, Fallahi-Sichani M (2019) Epigenetic mechanisns of escape from BRAF oncogene dependency. Cancers 11(10). pii: E1480. https://doi.org/10.3390/cancers11101480

  12. Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Rohwer N, Cramer T (2011) Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14:191–201

    Article  CAS  PubMed  Google Scholar 

  14. Mazure NM, Pouysségur J (2010) Hypoxia-induced autophagy: cell death or cell survival? Curr Opin Cell Biol 22:177–180

    Article  CAS  PubMed  Google Scholar 

  15. Saint-Martin A, Castañeda-Patlán MC, Robles-Flores M (2017) The role of hypoxia inducible factors in cancer resistance. J Cell Signal 2:154. https://doi.org/10.4172/2161-0495.1000154

    Article  CAS  Google Scholar 

  16. Matés JM, Di Paola FJ, Campos-Sandoval JA, Mazurek S, Márquez J (2020) Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev Biol 98:34–43. https://doi.org/10.1016/j.semcdb.2019.05.012

    Article  CAS  PubMed  Google Scholar 

  17. Zhou W, Wahl DR (2019) Metabolic abnormalities in glioblastoma and metabolic strategies to overcome treatment resistance. Cancer 11:1231. https://doi.org/10.3390/cancers11091231

    Article  CAS  Google Scholar 

  18. Saint-Martin A, Martínez-Ríos J, Castañeda-Patlán MC, Sarabia-Sánchez MA, Tejeda-Muñoz N, Chinney-Herrera A, Soldevila G, Bennelli R, Santoyo-Ramos P, Poggi A, Robles-Flores M (2019) Functional interaction of hypoxia inducible factor 2-alpha and autophagy mediates drug resistance in colon cancer cells. Cancer 11:755. https://doi.org/10.3390/cancers1106

    Article  CAS  Google Scholar 

  19. Li X, Zhou Y, Li Y, Yang L, Ma Y, Peng X et al (2029) Autophagy: a novel mechanism of chemoresistance in cancer. Biomed Pharmacother 119:109415

    Article  Google Scholar 

  20. Wang L, Shang Z, Zhou Y, Hu X et al (2018) Autophagy mediates glucose starvation induced glioblastoma cell quiescence and chemoresistance through coordinating cell metabolism, cell cycle, and survival. Cell Death Dis 9:213

    Article  PubMed  PubMed Central  Google Scholar 

  21. Galluzzi L, Bravo-San Pedro JM, Levine B, Green DR, Kroemer G (2017) Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat Rev Drug Discov 16:487–511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Thorburn J, Frankel A, Thorburn A (2009) Regulation of HMGB1 release by autophagy. Autophagy 5(2):247–256

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Steinbichler TB, Dudás J, Skvortsov S, Ganswindt U, Riechelmann H, Skvortsova II (2018) Therapy resistance mediated by cancer stem cells. Semin Cancer Biol 53:156–167

    Article  CAS  PubMed  Google Scholar 

  24. Abdullah LN, Chow EK-H (2013) Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2(1):3

    Article  PubMed  PubMed Central  Google Scholar 

  25. De Francesco EM, Sotgia F, Lisanti MP (2018) Cancer stem cells (CSCs): metabolic strategies for their identification and eradication. Biochem J 475:1611–1634

    Article  PubMed  PubMed Central  Google Scholar 

  26. De Angelis ML, Francescangeli F, La Torre F, Zeuner A (2019) Stem cell plasticity and dormancy in the development of cancer therapy resistance. Front Oncol 9:626

    Article  PubMed  PubMed Central  Google Scholar 

  27. Luo M, Brooks M, Wicha MS (2015) Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des 21:1301–1310

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Carnero A, Lleonart M (2016) The hypoxic microenvironment: a determinant of cancer stem cell evolution. Bioessays 38(Suppl 1):S65–S74

    Article  PubMed  Google Scholar 

  29. Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33:207–214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ et al (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7(9):1028–1034

    Article  CAS  PubMed  Google Scholar 

  31. Skvortsov S, Debbage P, Lukas P, Skvortsova I (2015) Crosstalk between DNA repair and cancer stem cell (CSC) associated intracellular pathways. Semin Cancer Biol 31:36–42

    Article  CAS  PubMed  Google Scholar 

  32. Scortegagna M, Ding K, Oktay Y, Gaur A, Thurmond F, Yan LJ, Marck BT, Matsumoto AM, Shelton JM, Richardson JA et al (2003) Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat Genet 35:331–340

    Article  CAS  PubMed  Google Scholar 

  33. Bertout JA, Majmundara AJ, Gordan JD, Lam JC, Ditsworth D, Keith B, Brown EJ, Nathanson KL, Simon MC (2009) HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A 106:14391–14396

    Google Scholar 

  34. Sotgia F, Ozsvaria B, Fiorillo M, De Francesco EM, Bonuccellia G, Lisanti MP (2018) A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX. Cell Cycle 17(17):2091–2100

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Jahanban-Esfahlan R, Seidi K, Manjili MH, Jahanban-Esfahlan A, Javaheri T, Zare P (2019) Tumor cell dormancy: threat or opportunity in the fight against cancer. Cancer 11:1207. https://doi.org/10.3390/cancers11081207

    Article  CAS  Google Scholar 

  36. Azvolinsky A (2017) How cancers evolve drug resistance. Features. The Scientist, April 2017 Issue

    Google Scholar 

  37. Tumeh PC, Harview CL, Yearley JH, Shintaku IP et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568–571

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Koyama S, Akbay EA, Li YY, Herter-Sprie GS et al (2016) Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun 7(10501):2016. https://doi.org/10.1038/ncomms10501

    Article  CAS  Google Scholar 

  39. Boulch M, Grandjean CL, Cazaux M, Bousso P (2019) Tumor immunosurveillance and immunotherapies: a fresh look from intravital imaging. Trends Immunol pii 40(11):1022–1034. . pii: S1471-4906(19)30190-5. https://doi.org/10.1016/j.it.2019.09.002

    Article  CAS  Google Scholar 

  40. Kalbasi A, Ribas A (2019) Tumour-intrinsic resistance to immune checkpoint blockade. Nature Rev Immunol 20(1):25–39. https://doi.org/10.1038/s41577-019-0218-4

    Article  CAS  Google Scholar 

  41. Farmer JR (2019) Testing immune-related adverse events in cancer immunotherapy. Clin Lab Med 39(4):669–683

    Article  PubMed  Google Scholar 

  42. Li D, Li X, Zhou WL, Huang Y, Liang X, Jiang L, Yang X, Sun J, Li Z, Han WD, Wang W (2019) Genetically engineered T cells for cancer immunotherapy. Signal Transduct Target Ther 4:35. https://doi.org/10.1038/s41392-019-0070-9. eCollection 2019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Schepisi G, Cursano MC, Casadei C, Menna C et al (2019) CAR-T cell therapy: a potential new strategy against prostate cancer. J Immunother Cancer 7(1):258. https://doi.org/10.1186/s40425-019-0741-7

    Article  PubMed  PubMed Central  Google Scholar 

  44. Sotillo E, Barrett DM, Black KL, Bagashev A et al (2015) Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 5(12):1282–1295

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work is supported by a grant from Consejo Nacional de Ciencia y Tecnología (FOSSIS 2017-289600) and by Programa de Apoyo a Proyectos de Investigación e Innovación Tecnológica (PAPIIT IV200220) to MRF.

Author information

Authors and Affiliations

  1. Department of Biochemistry, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico

    Martha Robles-Flores

Authors
  1. Martha Robles-Flores
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martha Robles-Flores .

Editor information

Editors and Affiliations

  1. Department of Biochemistry, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico

    Martha Robles-Flores

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Robles-Flores, M. (2021). Fighting Cancer Resistance: An Overview. In: Robles-Flores, M. (eds) Cancer Cell Signaling. Methods in Molecular Biology, vol 2174. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-0759-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-0759-6_1

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-0758-9

  • Online ISBN: 978-1-0716-0759-6

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation